Literature DB >> 21451970

Guillain-barré syndrome: modern theories of etiology.

Todd A Hardy1, Stefan Blum, Pamela A McCombe, Stephen W Reddel.   

Abstract

Guillain-Barré syndrome (GBS) is a classic failure of the immune system with a life-threatening attack upon a critical self-component. The active phase of the disease is short, concordant with the latency of a primary adaptive immune response. Triggers for GBS include infection and (rarely) vaccination; cross-reactivity between infectious and neural epitopes has been well demonstrated, particularly for Campylobacter jejuni and motor axonal forms of GBS in which non-protein gangliosides are antigenic. Most people are probably exposed to a GBS trigger, but only rarely does the disease develop. We propose that GBS illustrates competing determinants of the immune system's decision about whether to mount a response, and that in unlucky affected individuals, co-presentation of cross-reactive antigens with danger signals activating pattern-recognition receptors overcomes normal self-recognition such that a primary response is initiated that attacks the nerve. Then, in most cases of GBS, the response rapidly turns off, and second attacks rarely occur. This suggests active restoration of tolerance, and specific privileged site attributes of nerve and declining danger signals as the trigger wanes may contribute to this restoration. Standard immunosuppression has not been effective in GBS. We suggest this is because immune tolerance is already being restored by the time such therapies are initiated. This in turn suggests that improvements in GBS outcomes are likely to come from better protection of the nerve cells under attack while normal resumption of tolerance is permitted to proceed rather than exploring more aggressive immunosuppressive approaches.

Entities:  

Mesh:

Year:  2011        PMID: 21451970     DOI: 10.1007/s11882-011-0190-y

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  45 in total

1.  Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome.

Authors:  A Chiba; S Kusunoki; T Shimizu; I Kanazawa
Journal:  Ann Neurol       Date:  1992-06       Impact factor: 10.422

2.  On observing and analyzing disease versus signals.

Authors:  Rolf Zinkernagel
Journal:  Nat Immunol       Date:  2007-01       Impact factor: 25.606

3.  Guillain-Barré syndrome: incidence and mortality rates in US hospitals.

Authors:  Amer Alshekhlee; Zulfiqar Hussain; Badr Sultan; Bashar Katirji
Journal:  Neurology       Date:  2008-04-29       Impact factor: 9.910

4.  Self glycolipids as T-cell autoantigens.

Authors:  A Shamshiev; A Donda; I Carena; L Mori; L Kappos; G De Libero
Journal:  Eur J Immunol       Date:  1999-05       Impact factor: 5.532

5.  Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.

Authors:  L Ruts; J Drenthen; B C Jacobs; P A van Doorn
Journal:  Neurology       Date:  2010-04-28       Impact factor: 9.910

6.  An acute axonal form of Guillain-Barré polyneuropathy.

Authors:  T E Feasby; J J Gilbert; W F Brown; C F Bolton; A F Hahn; W F Koopman; D W Zochodne
Journal:  Brain       Date:  1986-12       Impact factor: 13.501

7.  Axonal degeneration in demyelinating disorders.

Authors:  R E Madrid; H M Wiśniewski
Journal:  J Neurocytol       Date:  1977-02

8.  The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

Authors:  T Lasky; G J Terracciano; L Magder; C L Koski; M Ballesteros; D Nash; S Clark; P Haber; P D Stolley; L B Schonberger; R T Chen
Journal:  N Engl J Med       Date:  1998-12-17       Impact factor: 91.245

Review 9.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

Authors:  Pieter A van Doorn; Liselotte Ruts; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2008-10       Impact factor: 44.182

10.  Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977.

Authors:  L B Schonberger; D J Bregman; J Z Sullivan-Bolyai; R A Keenlyside; D W Ziegler; H F Retailliau; D L Eddins; J A Bryan
Journal:  Am J Epidemiol       Date:  1979-08       Impact factor: 4.897

View more
  11 in total

1.  Cumulative risk of Guillain-Barré syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic.

Authors:  Claudia Vellozzi; Shahed Iqbal; Brock Stewart; Jerome Tokars; Frank DeStefano
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

Review 2.  Revisiting the old link between infection and autoimmune disease with commensals and T helper 17 cells.

Authors:  J Magarian Blander; Miriam B Torchinsky; Laura Campisi
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 3.  Four decades of leading-edge research in the reproductive and developmental sciences: the Infant Primate Research Laboratory at the University of Washington National Primate Research Center.

Authors:  Thomas M Burbacher; Kimberly S Grant; Julie Worlein; James Ha; Eliza Curnow; Sandra Juul; Gene P Sackett
Journal:  Am J Primatol       Date:  2013-07-19       Impact factor: 2.371

Review 4.  Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?

Authors:  Maria Vadalà; Dimitri Poddighe; Carmen Laurino; Beniamino Palmieri
Journal:  EPMA J       Date:  2017-07-20       Impact factor: 6.543

5.  Acute demyelinating polyneuropathy after lung transplantation: guillain-barré syndrome or tacrolimus toxicity?

Authors:  Nirmal S Sharma; Keith M Wille; Charles W Hoopes; Enrique Diaz-Guzman
Journal:  Case Rep Transplant       Date:  2014-08-11

6.  The Emergence of Zika Virus as a Global Health Security Threat: A Review and a Consensus Statement of the INDUSEM Joint working Group (JWG).

Authors:  Veronica Sikka; Vijay Kumar Chattu; Raaj K Popli; Sagar C Galwankar; Dhanashree Kelkar; Stanley G Sawicki; Stanislaw P Stawicki; Thomas J Papadimos
Journal:  J Glob Infect Dis       Date:  2016 Jan-Mar

7.  The clinical characteristics and short-term prognosis in elderly patients with Guillain-Barré syndrome.

Authors:  Bing Zhang; Xiujuan Wu; Donghui Shen; Ting Li; Chunrong Li; Mei Mao; Hong-Liang Zhang; Kangding Liu
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

8.  The effects of vasoactive intestinal peptide in the rat model of experimental autoimmune neuritis and the implications for treatment of acute inflammatory demyelinating polyradiculoneuropathy or Guillain-Barré syndrome.

Authors:  Hong Jiao; Huan Ren
Journal:  Drug Des Devel Ther       Date:  2018-11-06       Impact factor: 4.162

9.  Reactivation of Chronic Hepatitis C as a Potential Trigger for Guillain-Barré Syndrome.

Authors:  Ogochukwu Molokwu; Brittany M Young; Manjit Singh; Krishe Menezes; Raza Mian
Journal:  Cureus       Date:  2019-07-26

10.  Comment on: Zika virus and Guillain-Barré syndrome in Bangladesh.

Authors:  Yhojan Rodríguez; Juan-Manuel Anaya
Journal:  Ann Clin Transl Neurol       Date:  2018-07-13       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.